Stachowicz M, Mazurek U, Nowakowska-Zajdel E, Niedworok E, Fatyga E, Muc-Wierzgon M
Department of Molecular Biology, Silesian Medical University, Sosnowiec, Poland.
J Biol Regul Homeost Agents. 2010 Jul-Sep;24(3):287-95.
The purpose of this study is to examine serum concentration of leptin and that of the soluble form, the Ob-Re receptor, in patients with colorectal cancer, as well as to examine the level of leptin mRNA and that of its receptors, Ob-Ra and Ob-Rb, in large intestine specimens collected from patients with colorectal cancer, depending on cancer clinical and pathological progression and BMI. A total of 146 patients with colorectal cancer in a I-IV stage scale according to the TNM Classification were enrolled. The patients were divided into two groups according to BMI calculations based on body weight and height: a Study group (BMI greater than or equal to 25 kg/m2) of 75 patients aged 57 plus or minus 4.5 years and a Control group (20 less than BMI less than 25 kg/m2) of 71 patients aged 60 plus or minus 5 years. The experimental part of the work was performed in two stages: Stage I regarding the assay of leptin concentration and that of its soluble receptor, Ob-Re, in the serum of patients with the use of the ELISA method; and Stage II to determine the number of leptin mRNA copies and two isoforms of leptin receptors, Ob-Ra and Ob-Rb, using the QRT-PCR method in tissue specimens collected from 146 patients. In our results the concentration of serum leptin and Ob-Re was not dependent on the stage of clinical and pathological progression of the cancer. There was a statistically significant higher serum leptin level in colon cancer patients who were overweight or obese compared to patients with normal weight. No presence of mRNA of the gene encoding leptin was found in tissues collected from colorectal cancer patients. The number of mRNA copies of Ob-Rb was statistically significantly higher in all the study groups compared to the reference tissues.
本研究旨在检测结直肠癌患者血清中瘦素及其可溶性形式（Ob-Re受体）的浓度，以及根据癌症临床和病理进展情况及体重指数（BMI），检测从结直肠癌患者收集的大肠组织标本中瘦素mRNA及其受体Ob-Ra和Ob-Rb的水平。根据TNM分类标准，共纳入146例I-IV期的结直肠癌患者。根据体重和身高计算的BMI将患者分为两组：研究组（BMI大于或等于25kg/m²）75例，年龄57±4.5岁；对照组（20＜BMI＜25kg/m²）71例，年龄60±5岁。实验部分分两个阶段进行：第一阶段使用ELISA方法检测患者血清中瘦素浓度及其可溶性受体Ob-Re的浓度；第二阶段使用QRT-PCR方法测定从146例患者收集的组织标本中瘦素mRNA拷贝数以及瘦素受体的两种亚型Ob-Ra和Ob-Rb。在我们的研究结果中，血清瘦素和Ob-Re的浓度并不取决于癌症临床和病理进展的阶段。与体重正常的患者相比，超重或肥胖的结肠癌患者血清瘦素水平在统计学上显著更高。在从结直肠癌患者收集的组织中未发现编码瘦素的基因的mRNA。与对照组织相比，所有研究组中Ob-Rb的mRNA拷贝数在统计学上显著更高。
